Bonaldo
Alessio Bonaldo, Norrkoping SE
Patent application number | Description | Published |
---|---|---|
20150082796 | BURNER - A burner of a gas turbine extending along an axis is provided having in axial order: a swirler section, mixing section, outlet section, and main combustion zone. The swirler section has swirler vanes to swirl a stream of fuel and oxygen containing gas entering therein in a circumferential direction. The mixing section conducts the premix of fuel and oxygen containing gas to the outlet section. The outlet section discharges the premix into the combustion zone expanding the flow of premix from a smaller axial cross section of the mixing section to a larger cross section of the combustion zone which streamlines the flow to diverge radially. A surface of the outlet section facing the flow of the premix is provided with first fuel nozzles injecting fuel into the premix into a radial inwardly inclined direction before the flow of the premix enters the outlet section into the combustion zone. | 03-26-2015 |
Jean Bonaldo, Upland, CA US
Patent application number | Description | Published |
---|---|---|
20150141937 | Medical Luer Connector - A luer medical connector having a male luer body for connection with a female luer assembly which includes a female luer body, a fluid channel insert within the female luer body, an elastomeric seal between the female luer body and the male luer body, and an elastomeric stopper at a proximal end of the female luer body. | 05-21-2015 |
Myrna Cristina Bonaldo, Rio De Janeiro BR
Patent application number | Description | Published |
---|---|---|
20100297167 | Method for the Production of Recombinant Virus, DNA Constructs, Recombinant Virus and Vaccine Compositions - The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, they present in the 5′ region, nucleotides present in the 5′ edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3′ region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein E of this vector virus or equivalent functional sequences, and not compromising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of on structural NS1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having the heterolog sequences integrated in the viral genome according to the insertion described in (b) and, like that, expressing the heterolog antigene in such way that it can induce an appropriate immune response. The present invention is also addressed to vaccine compositions to immune against the Flavivirus and/or other pathogens. | 11-25-2010 |
20150024003 | METHOD FOR THE PRODUCTION OF RECOMBINANT VIRUS, DNA CONSTRUCTS, RECOMBINANT VIRUS AND VACCINE COMPOSITIONS - The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, the present in the 5′ region nucleotides present in the 5′ edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3′ region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein E of this vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of nonstructural NS1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having the heterolog sequences integrated in the viral genome according to the insertion described in (b) and, like that, expressing the heterolog antigene in such way that it can induce an appropriate immune response. The present invention is also addressed to vaccine compositions to immune against the Flavivirus and/or other pathogens. | 01-22-2015 |
Myrna Cristina Bonaldo, Jacarepagua BR
Patent application number | Description | Published |
---|---|---|
20120321655 | LENTIVIRUS VACCINE BASED ON THE RECOMBINANT VIRAL VACCINE AGAINST YELLOW FEVER - The present invention relates to an attenuated, recombinant viral vaccine against yellow fever which expresses heterologous sequences of a lentivirus and is used as an immunisation agent to induce an immune response to lentivirus. | 12-20-2012 |
Paolo Bonaldo, Orsago IT
Patent application number | Description | Published |
---|---|---|
20090036382 | TGF-Beta Modulators and Use Thereof - The present invention relates to molecules preferably of polypeptide nature with negative regulatory activity on the amount or activity of TGF-β through direct interaction with pro-TGF-β, and containing as active region a cysteine-rich polypeptide sequence defined as “EMI domain”, or its subfragments, wherein said “EMI domain” has at least 25% sequence homology to the ID NO2 sequence for pharmaceutical use. Even more preferably said polypeptide sequence consists of the EMI domain of the following proteins: emilin-1, emilin-2 and/or multimerin-2 or their subfragments having a length of at least 6 amino acids, capable of inhibiting the conversion of pro-TGFβ to mature TGFβ as anti-hypertensive drugs and polypeptides active on the cardiovascular system. The invention extends to the use of molecules which are known to negatively regulate TGF-β and to molecules which interfere with TGF-β binding to its receptors, or to inhibitors of TGF-β mRNA synthesis or TGF-β expression for the same therapeutic uses as anti-hypertensive drugs and polypeptides active on the cardiovascular system. | 02-05-2009 |
Paolo Bonaldo, Padova IT
Patent application number | Description | Published |
---|---|---|
20120329800 | TREATMENT OF MUSCULAR DYSTROPHIES AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS - Administration of a monoamine oxidase inhibitor is useful in the prevention and treatment of muscle dystrophy. Methods and compositions for inhibiting the production of reactive oxygen species in a muscle cell overproducing reactive oxygen species are provided herein. | 12-27-2012 |